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Background. Treatment options for progressive IgA nephr-
opathy are limited. Methods. We performed a small, random-
ized controlled trial to evaluate the effects of prednisolone (PSL,
30 mg/dL, gradually tapered to 5 mg/dL over two years) plus 50
mg/day of losartan (LST, an angiotensin II receptor blocker) or
PSL alone on IgA nephropathy. We separated 38 patients (age,
33  ± 11 years; creatinine clearance, 103 ± 31 mL/min; pro-
teinuria, 1.6 ± 0.5 g/day) into two groups that were treated with
either PSL plus LST or PSL alone, and compared the proteinuria
and creatinine clearance after two years. Baseline and histo-
pathological data did not significantly differ between the two
groups. Results. Two years of treatment in both groups signifi-
cantly decreased proteinuria compared with baseline, and PSL
plus LST (from 1.6 ± 0.6 to 0.3 ± 0.1 g/day, p < 0.05) was
more effective than PSL alone (from 1.6 ± 0.3 to 0.5 ± 0.1 g/
day, p < 0.05). Creatinine clearance in both groups was simi-
lar at the start of study but significantly differed at the end of
the study (PSL plus LST, 104.3 ± 36.4 to 100.4 ± 38.9 mL/
min; PSL alone, 103.4 ± 28.5 to 84.8 ± 34.3 mL/min, p <
0.05). Conclusions. Combined therapy with PSL plus LST
appears to be more effective than PSL alone in reducing
proteinuria and protecting renal function in patients with IgA
nephropathy.
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INTRODUCTION
Immunoglobulin A nephropathy (IgAN) is the most
prevalent type of primary glomerulonephritis worldwide
and in Japan.[1,2] Among the clinical and laboratory fea-
tures, hypertension and proteinuria are important predic-
tors of a poor outcome.[3] Proteinuria causes renal damage
that leads to the more rapid progression of renal diseases
toward end-stage renal failure.[4] Because angiotensin II
plays a critical role in the pathogenesis of proteinuria,
angiotensin-converting enzyme (ACE) inhibitors are often
administered to patients with proteinuric nephropathies.[4–6]
Among the many factors that affect the progression of
IgAN, blood pressure (BP) is one of the most important.[7]
However, although antihypertensive approaches applied to
humans and other experimental animals with chronic
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kidney diseases (CKD) have proven positive, the effects of
such treatment on the initial stage of IgAN remain
unknown. Some major trials of antihypertensive therapy in
renal diseases with proteinuria have suggested that optimal
BP control protects renal function.[8] A recent study has
shown that ACE inhibitors and angiotensin II receptor
blockers (ARBs) can reduce glomerular hypertension, pro-
teinuria, and glomerular size-selectivity,[9] and clinical tri-
als have shown that these drugs also slow the progression
of CKD.[4–7] Some randomized clinical trials and retro-
spective cohort studies of patients with IgAN have found
that ACE inhibitors and/or ARBs moderately lower uri-
nary protein excretion.[9–11] However, whether or not ACE
inhibitors and ARBs preserve renal function in patients
with IgAN remains obscure.[8–10] Moreover, the early initi-
ation of antihypertensive treatment for IgAN has still not
been investigated.
Corticosteroids have been used for more than 20 years
to treat IgAN because of their anti-inflammatory and
immunosuppressive properties. An ideal protocol of ste-
roid therapy is required that can prevent the progression of
IgAN with minimal toxicity. Katafuchi et al.[11] have
recently described a randomized, controlled trial of 90
adult IgAN patients who received either supportive ther-
apy or low dose prednisolone for two years. Prednisolone
lowered proteinuria after two years but did not improve
renal survival. Therefore, they suggested that the low dose
of PSL in the protocol might have caused the discrepancy
between the effects on proteinuria and renal survival.[11]
Moreover, two other randomized trials of small patient
cohorts revealed that steroids similarly decreased pro-
teinuria but did not affect renal function.[12,13] Because we
found that both PSL and ARBs reduced proteinuria in
IgAN, we questioned whether a combination of PSL and
ARBs in the setting of normotensive and moderately pro-
teinuric IgAN with moderate histological features could
improve the anti-proteinuric effect and preserve renal
function better than PSL alone.
SUBJECTS AND METHODS
This prospective, randomized controlled clinical trial
proceeded in accordance with the standards of the Ethics
Committee of Nagasaki Municipal Medical Center, and all
patients provided written, informed consent to participate.
Patients
Between 2000 and 2003, IgAN was newly diagnosed in
66 of 189 biopsies at Nagasaki Municipal Medical Center.
Of 66 patients with IgAN, 40 patients satisfied the follow-
ing criteria and were enrolled in the trial. Entry criteria were
normal BP of <140/90 mmHg; mean arterial pressure <107
mmHg, persistent mild to moderate proteinuria of 1.6 ± 0.5
g/day (range, 1.0–2.6), and normal or mild to moderately
reduced but stable renal function (creatinine clearance; Ccr
>50 mL/min/1.73m2), with a renal glomerular score
between 4 and 7 according to Katafuchi’s scale.[14] Patients
with systemic diseases such as diabetes, lupus erythemato-
sus, chronic liver diseases, renal allografts, and Henoch-
Schönlein purpura were excluded. The patients did not
receive ACE inhibitors, ARBs, immunosuppressive ther-
apy, or diuretic and statin treatment throughout the study.
Administration of PSL Plus LST
The angiotensin II receptor blocker losartan (LST) was
combined with PSL and administered to 22 patients with
IgAN, and PSL alone was given to another 18. Two
dropped out of the study due to postural hypotension. All
statistical calculations were thus obtained from data gener-
ated by 38 patients (18 females and 20 males; age, 33.5 ±
11.0 years; range, 16–52 years), who were randomly
assigned to the PSL or combined group. Twenty patients
aged 34.6 ± 12.0 (8 females and 12 males) received PSL
orally at sequential doses of 30 mg/dL for two months, 25
mg/dL for two months, 20 mg/dL for two months, 15 mg/
dL for six months, 10 mg/dL for twelve months, and 5 mg/
dL for one month, together with 50 mg of LST daily. Eigh-
teen patients aged 32.3 ± 10.6 (10 females and 8 males)
received PSL alone over a period of 24 months. Dipy-
ridamole (300 mg/dL) was administered to both groups.
Clinical and Laboratory Procedures
Complete medical histories were obtained and physi-
cal examinations were performed on all patients to obtain
baseline data at the start of the study. Side effects were
examined, and the patients were questioned about their
symptoms once each month during follow-up. The patients
were instructed to take the medication once after awaken-
ing every morning, and blood samples were tested 3 h later.
Baseline laboratory tests included a complete blood count,
serum chemistry, and 24-h urine collection for protein.
Blood pressure and serum creatinine were tested again one
week after starting the protocol. The patients remained on
their usual diet (free intake of salt and protein) for the dura-
tion of the study. The treatment effects were prospectively
assessed monthly. The patients were seated for BP and
heart rate measurements. Protein excretion was evaluated
in 24-h urine samples after 6, 12 and 24 months. Serum and
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routine laboratory methods using a JEOL JCA-BM1650
autoanalyzer (JEOL, Tokyo, Japan). We evaluated the Ccr
after 6, 12, and 24 months using the Gault-Cockcroft equa-
tion.[15] The same clinician measured BP in seated patients
once each after at least 15 min of rest, using a standard
sphygmomanometer with an appropriately sized cuff. The
values obtained from three measurements at 3 min intervals
were averaged. The first and fifth Korotkoff sounds were
taken as systolic and diastolic BP (SBP and DBP), respec-
tively. Mean arterial pressure (MAP) was calculated as the
sum of one-third of the SBP and two-thirds of the DBP.
Pathological Examination
Glomerular, interstitial, and vascular lesions were
scored by assessing samples stained with hematoxylin and
eosin, periodic acid-Schiff, trichrome, and silver, using
light microscopy, immunofluorescence, and electric
microscopy. The immunofluorescence findings were clas-
sified between none (–) and 3+ according to the intensity of
fluorescence of each specimen. The diagnosis was limited
to primary mesangial proliferative glomerulonephritis with
a predominant deposition of IgA in the mesangium. The
specific pathological features of the patients were scored
by light microscopy as described by Katafuchi et al.[14]
Glomerular lesions (total score, 0–12) included glomerular
hypercellularity, glomerular segmental types, and glomeru-
lar sclerosis. The score for each glomerular lesion was as
fellows: 0, none; 1, <10% of glomeruli involved; 2, 10–
24%; 3, 25–49%; 4, 50+% of glomeruli involved. The
severity of interstitial cell infiltration, interstitial fibrosis,
tubular atrophy, arterial wall thickening, and arteriolar hya-
line change in each patient was semi-quantified (total
score, 0–9) from 0 to 3 according to the ratio (%) of injured
tissue: 0, none; 1, <25%; 2, 25–49%; 3, 50+%.
Statistical Analysis
All data are expressed as means ± SD. We applied an
unpaired Student’s t-test to determine the significance of
differences among the three treatment groups. Discrete
data were examined using the X2 analysis. Values of p <
0.05 were considered to indicate statistical significance.
RESULTS
Baseline Data
Twenty patients received PSL plus LST and 18
patients received PSL alone for 24 months. The two
groups did not significantly differ in terms of age, gender,
BP, baseline laboratory values (see Table 1) or Katafu-
chi’s grading of renal lesions at baseline (see Table 2).
Comparison of Efficiency of Therapy in Two Groups
Primary end points could be analyzed in 38 of the 40
patients at the end of the 24 months period. Two patients
in the PSL + LST group developed postural hypotension.
After 24 months of treatment, 24-h urinary protein excre-
tion decreased by 50+% in 18 of the 20 patients (90%) in
the PSL + LST group and in 15 of 18 (83%) in the PSL
group compared with baseline values (p < 0.05). The
serum creatinine of four patients in the PSL group
increased ≥50%. Table 3 shows the clinical follow-up data
for the two groups. The SBP was significantly decreased
at 12 and 24 months of treatment in the PSL + LST and
PSL groups compared with baseline (both p < 0.01), and
DBP was significantly decreased at 24 months of treat-
ment in the PSL + LST group compared with baseline and
the PSL group (p < 0.01). However, DBP did not change
significantly in the PSL group (see Figure 1). The level of
serum creatinine remained unchanged in the PSL + LST
group, but was significantly increased in the PSL group at
Table 1 
Comparison of baseline characteristics between patient groups
Characteristic PSL + LST (n=20) PSL (n = 18) p
Male/female 12/8 8/10 0.53
Age, y 34 ± 12 32 ± 10 0.67
BMI, kg/m2 21.2 ± 3.1 19.9 ± 1.7 0.30
Systolic BP, 
mmHg
120 ± 8 121 ± 70 . 9 0
Diastolic BP, 
mmHg
73 ± 6 75 ± 70 . 5 9
Heart rate, 
beats/min
71 ± 4 72 ± 60 . 7 8
Na, mEq/L 142.5 ± 1.4 141.2 ± 1.4 0.65
K, mEq/L 4.3 ± 0.3 4.4 ± 0.2 0.68
BUN, mg/dL 14.1 ± 4.4 14.7 ± 3.7 0.75
sCr, mg/dL 0.8 ± 0.2 0.7 ± 0.1 0.52
Ccr ml/min/
1.73 m2
104 ± 36 103 ± 28 0.95
Proteinuria, 
g/24 h
1.6 ± 0.6 1.6 ± 0.4 0.75
Serum IgA, 
mg/dL
330 ± 75 366 ± 131 0.47
Abbreviations: PSL = prednisolone, LST = losartan, BMI =
body mass index, BP = blood pressure, BUN = blood urea nitrogen,
sCr = serum creatinine, Ccr = creatinine clearance, IgA = immu-
noglobulin A.444 Y. Horita et al.
12 and 24 months of treatment compared with baseline
(p < 0.05, respectively). The Ccr fell significantly at 12
and 24 months of treatment in the PSL group compared
with baseline (p < 0.05, respectively) but remained
unchanged in the PSL+LST group. The Ccr was lower in
the PSL than in the PSL+LST group at 12 and 24 months
of treatment (see Figure 2). Proteinuria significantly
decreased at 12 and 24 months of treatment in both groups
compared with baseline (p < 0.05 in both groups, respec-
tively), and PSL+LST was more effective than PSL alone at
12 and 24 months (p < 0.05, respectively; Figure 3). Total
protein levels significantly increased compared with the base-
line at 12 and 24 months of treatment in the PSL+LST group,
but remained unchanged in the PSL group (see Table 3).
DISCUSSION
The present study compared the efficiency of com-
bined therapy with PSL (30 mg/day induction; 5 mg/day
maintenance) + LST (50 mg/day) and PSL therapy alone
in patients with IgAN and moderately severe histological
characteristics defined as glomerular Katafuchi’s scores of
4 to 7.[14] Our preliminary results demonstrated that LST
decreases proteinuria in IgAN receiving PSL. Notably, the
more rigorous BP control achieved with LST (mean BP of
101/65 mmHg) might have inhibited the reduction in GFR
Table 2 
Comparison of baseline histopathologic features 
between patient groups
Characteristic PSL + LST (n = 20) PSL (n = 18) p
Glomerular 
hypercellularity
1.3 ± 0.4 1.4 ± 0.5 0.29
Glomerular 
segmental 
lesions
1.5 ± 0.5 1.5 ± 0.5 0.50
Glomerular 
global sclerosis
1.0 ± 0.9 1.1 ± 0.8 0.43
Cellular 
(fibrocellular) 
crescents
0.5 ± 0.7 0.7 ± 0.9 0.49
Tuft adhesion 0.9 ± 0.3 1.1 ± 0.6 0.36
Glomerular score 5.2 ± 0.5 6.0 ± 0.6 0.34
Interstitial cell 
infiltration
1.3 ± 0.6 1.5 ± 0.7 0.44
Interstitial fibrosis 1.1 ± 0.7 1.2 ± 0.8 0.74
Tubular atrophy 1.1 ± 0.7 1.4 ± 1.0 0.41
Arterial wall 
thickening
0.7 ± 0.8 0.8 ± 0.5 0.64
Arteriolar hyaline 
change
1.1 ± 1.1 0.6 ± 1.2 0.41
Abbreviations: PSL = prednisolone, LST = losartan.
Table 3 
Comparison of clinical follow-up data between patient groups
Characteristic Group Baseline 12 months 24 months
BMI, kg/m2 PSL + LST 21.2 ± 3.1 21.4 ± 3.2 21.4 ± 3.1
PSL 19.9 ± 1.7 20.1 ± 2.0 20.1 ± 1.8
Systolic BP, mmHg PSL + LST 120 ± 81 0 2  ± 9*# 101 ± 8*#
PSL 121 ± 71 2 1  ± 11 125 ± 12
Diastolic BP, mmHg PSL + LST 73 ± 66 8  ± 8 65 ± 6*#
PSL 75 ± 77 5  ± 8 75 ± 10
K, mEq/L PSL + LST 4.3 ± 0.3 4.4 ± 0.2 4.4 ± 0.3
PSL 4.4 ± 0.2 4.4 ± 0.3 4.4 ± 0.4
sCr, mg/dL PSL + LST 0.8 ± 0.2 0.8 ± 0.2 0.8 ± 0.2
PSL 0.7 ± 0.1 0.9 ± 0.1** 0.9 ± 0.2**
Ccr ml/min/1.73 m2 PSL + LST 104 ± 36 102 ± 42 100 ± 38
PSL 103 ± 28 86 ± 32** 84 ± 34**
Proteinuria, g/24 h PSL + LST 1.6 ± 0.6 0.3 ± 0.1*# 0.3 ± 0.1*#
PSL 1.6 ± 0.4 0.5 ± 0.2**# 0.5 ± 0.1**#
Total protein, g/dL PSL + LST 6.0 ± 0.4 6.6 ± 0.4* 6.7 ± 0.4*
PSL 6.2 ± 0.2 6.3 ± 0.2 6.4 ± 0.3
Abbreviations: BMI = body mass index, BP = blood pressure, BUN = blood urea nitrogen, sCr = serum creatinine, Ccr = creatinine
clearance.
*Compared with baseline, p < 0.01.
**Compared with baseline, p < 0.05.
#Comparison between PSL + LST and PSL-alone, p < 0.05.Steroids and Losartan in IgA Nephropathy 445
in patients with IgAN compared with those under nor-
mal BP control, whereas PSL alone did not. This finding
suggests that the combination of PSL + LST can be
safely administered to patients with IgAN. Our study
indicates that PSL + LST more effectively reduces pro-
teinuria and protects renal function in patients with
IgAN than PSL monotherapy. Because Katafuchi et
al.[14] revealed evidence of a mild protective effect of
dipyridamole on renal survival in patients with IgAN,
we administered dipyridamole to all patients in the
present study.
Some trials were considered to be of sufficient quality
to be included in a recent meta-analysis of immunosup-
pressive treatments for IgAN.[16] That analysis revealed
that corticosteroid therapy might reduce proteinuria and
the risk of end-stage renal disease (ESRD). Pozzi et al.[17]
recently found from a ten-year follow-up of a large Italian
study that corticosteroids confer impressive benefits in
terms of reducing proteinuria and preventing ESRD. How-
ever, their high-dose corticosteroid regimen, (three
courses of intravenous methylprednisolone, 1 g/day, for
three consecutive days plus oral prednisolone, 0.5 mg/kg,
on alternate days for six months), is regarded by many
physicians as likely to carry considerable toxicity, even
though none has been reported by investigators.[18] In our
study, although the serum creatinine of four patients in the
PSL group increased ≥50%, no severe side effects were
observed in the PSL and PSL + LST group. Notably, a
renin-angiotensin system blockade has only been applied
to a minority of patients, and although equally distributed
among the participants, the achieved BP was not in line
with current recommendations.[18] Moreover, a recent ran-
domized, prospective, controlled study of corticosteroids
(20 mg/day induction; 5 mg/day maintenance) of Japanese
patients found only a modest reduction in proteinuria with
no difference in renal survival.[11] Katafuchi et al.[11] had
been described that the absence of renoprotection might be
to an insufficient dose of PSL, without mentioning of the
extent of BP control.
Some specific evidence from patients with IgAN jus-
tifies strict BP control: in one small randomized, prospec-
tive, controlled study, a mean BP of 129/70 mmHg
stabilized Ccr over three years, whereas the mean Ccr
declined in patients with a BP of 136/76 mmHg at a rate of
13 mL/min over three years.[19] Therefore, Barratt et al.[18]
proposed that corticosteroids should be considered only
when proteinuria continues (>1 g/24 h) despite tight BP
control (<125/75 mmHg) and with a maximal renin-
angiotensin system blockade. Although we stabilized BP
at a mean of 101/65 mmHg Ccr over two years with PSL
+ LST, a definite conclusion from this preliminary study
of few patients within in a short observation period cannot
be drawn.
Figure 1. Blood pressure levels between the two groups.
*Compared with baseline, p < 0.01; **compared with baseline,
p < 0.05; #comparison between the PSL + LST group and PSL-
alone group, p < 0.05. Abbreviations: PSL = prednisolone; LST
= losartan.
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Figure 2. Creatinine clearance levels between the two groups.
*Compared with baseline, p < 0.05. Abbreviation:
Ccr=creatinine clearance.
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In conclusion, this preliminary study indicated that
therapy with PSL and LST is more effective than that with
PSL alone in reducing proteinuria and protecting renal
function in patients with moderately proteinuric IgAN and
moderate histological features. Future studies will deepen
understanding about this important clinical correlation,
and specifically allow determination of the ideal target
range of BP and dose of PSL.
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